Antibody avidity meets many myeloma In the ongoing try to find progressive remedies to battle refractory and relapsed most cancers, new preclinical work in multiple myeloma shows that increasing binding avidity by concentrating on two antigens in one T mobile-partaking trispecific antibody boosts anti-tumor activity and minimizes the probability of